Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
AI drug developer Basecamp Research just raised $140 million in a Series C round, pushing its valuation to $800 million. The London-based company plans to use the funds to advance its EDEN biological foundation models and develop in-body cell reprogramming therapies for cancer and autoimmune diseases — potentially at a fraction of current treatment costs.
Basecamp Research, a London-based AI drug developer, has closed a $140 million Series C funding round, valuing the company at $800 million. The oversubscribed round was led by S32 and drew participation from heavyweights including Nvidia, Anthropic's Anthology Fund, the NATO Innovation Fund, and the Rockefeller Foundation. The fresh capital will go toward training a new generation of its EDEN biological foundation models and advancing a pipeline of AI-designed therapies toward clinical development.
At the heart of Basecamp's approach is EDEN — a foundation model trained on a proprietary genomic dataset assembled through partnerships across more than 30 countries. The technology is designed to generate drug candidates based on disease information and, notably, to reprogram patients' cells inside the body. The company says this could make cell therapies more customizable and easier to administer than today's options, which can cost hundreds of thousands of dollars per patient for conditions like cancer and autoimmune diseases.
By the Numbers:
Why it matters: Current cell therapies are notoriously expensive and logistically complex. If Basecamp's in-body reprogramming approach delivers on its preclinical promise, it could dramatically lower costs and broaden patient access — a potential game-changer for oncology and autoimmune care.
